Abstract
Chemokines and their receptors play critical roles in leukocyte trafficking during inflammatory processes. Although the role of chemokine receptors (CKRs) in cancer biology is a relatively new field of study, a growing body of data suggest that a number of CKRs, including CXCR4, CCR4, CCR7, and CCR10, may play diverse of roles in cancer growth, cancer metastasis, cancer angiogenesis, or the composition of the cancer microenvironment. Preclinical models of cancer indicate that cancer antagonists, most notably those for CXCR4, can block cancer growth either directly or by altering the cancer stroma. Highthroughput screening methods to identify effective CKR antagonists have been developed, but specificity, potency, and drug-delivery of validated candidate compounds remain issues that result in the clinical failure of many initially promising candidates. The recent approval of a CCR5 receptor antagonist in HIV suggests that safe, effective small molecular antagonists for other CKRs may not be far away. There is still a clear need to extend our understanding of the signalling pathways by which CKRs facilitate cancer processes. Because of the role of CKRs in cancer cell survival, the combination of CKR antagonists with traditional chemotoxic agents or with immunotherapy is an alluring strategy since this increases the specificity of treatment to the cancer and potentially limits additional systemic side effects.
Current Pharmaceutical Design
Title: Chemokine Receptors as Targets for Cancer Therapy
Volume: 15 Issue: 7
Author(s): Xuesong Wu, Vivian C. Lee, Eric Chevalier and Sam T. Hwang
Affiliation:
Abstract: Chemokines and their receptors play critical roles in leukocyte trafficking during inflammatory processes. Although the role of chemokine receptors (CKRs) in cancer biology is a relatively new field of study, a growing body of data suggest that a number of CKRs, including CXCR4, CCR4, CCR7, and CCR10, may play diverse of roles in cancer growth, cancer metastasis, cancer angiogenesis, or the composition of the cancer microenvironment. Preclinical models of cancer indicate that cancer antagonists, most notably those for CXCR4, can block cancer growth either directly or by altering the cancer stroma. Highthroughput screening methods to identify effective CKR antagonists have been developed, but specificity, potency, and drug-delivery of validated candidate compounds remain issues that result in the clinical failure of many initially promising candidates. The recent approval of a CCR5 receptor antagonist in HIV suggests that safe, effective small molecular antagonists for other CKRs may not be far away. There is still a clear need to extend our understanding of the signalling pathways by which CKRs facilitate cancer processes. Because of the role of CKRs in cancer cell survival, the combination of CKR antagonists with traditional chemotoxic agents or with immunotherapy is an alluring strategy since this increases the specificity of treatment to the cancer and potentially limits additional systemic side effects.
Export Options
About this article
Cite this article as:
Wu Xuesong, Lee C. Vivian, Chevalier Eric and Hwang T. Sam, Chemokine Receptors as Targets for Cancer Therapy, Current Pharmaceutical Design 2009; 15 (7) . https://dx.doi.org/10.2174/138161209787582165
DOI https://dx.doi.org/10.2174/138161209787582165 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multiple Roles of Annexin A2 in Post-Transcriptional Regulation of Gene Expressio
Current Protein & Peptide Science The Application of Stimuli-responsive Nanocarriers for Targeted Drug Delivery
Current Topics in Medicinal Chemistry Drug Targeting Strategies for Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Magnetic Hyperthermia with Magnetic Nanoparticles: A Status Review
Current Topics in Medicinal Chemistry Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy
Current Molecular Pharmacology Perspectives on Brain-Targeting Drug Delivery Systems
Current Pharmaceutical Biotechnology Antiangiogenic Therapy
Current Pharmaceutical Design Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Anti-Cancer Agents in Medicinal Chemistry The Blood-Brain/Tumor Barriers: Challenges and Chances for Malignant Gliomas Targeted Drug Delivery
Current Pharmaceutical Biotechnology Ceramide and Sphingosine-1-Phosphate in Cell Death Pathways : Relevance to the Pathogenesis of Alzheimer's Disease
Current Alzheimer Research Exploration of Chemical Space Based on 4-Anilinoquinazoline
Current Medicinal Chemistry Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Cholangiocarcinoma Therapeutics: An Update
Current Cancer Drug Targets Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy
Mini-Reviews in Medicinal Chemistry Introduction: MMPs, ADAMs/ADAMTSs Research Products to Achieve Big Dream
Anti-Cancer Agents in Medicinal Chemistry Undermining Tumor Angiogenesis by Gene Therapy: An Emerging Field
Current Gene Therapy Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
Recent Patents on Anti-Cancer Drug Discovery Mitophagy in Carcinogenesis and Tumour Progression- A New Paradigm with Emerging Importance
Anti-Cancer Agents in Medicinal Chemistry The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research Small Molecule Complementarity As A Source of Novel Pharmaceutical Agents and Combination Therapies
Current Pharmaceutical Design